drug
afatinib dimaleate
Marketedupdated 6mo agoby Boehringer Ingelheim Corp
Approvedcommunity read0 votes
indications
investigational
NSCLC
all catalysts(0)
nothing on the calendar yet
Trials studying afatinib dimaleate
Patent cliff
source: FDA Orange Bookfirst barrier falls
May 9, 2027
170 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (30)
- Jan 5, 2031patentUS 10004743*PED4.1y
- Jan 5, 2031patentUS 10004743*PED4.1y
- Jan 5, 2031patentUS 10004743*PED4.1y
- Jul 5, 2030formulationUS 100047433.6y
- Jul 5, 2030formulationUS 100047433.6y
- Jul 5, 2030formulationUS 100047433.6y
- Jun 19, 2030patentUS 8545884*PED3.6y
- Jun 19, 2030patentUS 8545884*PED3.6y
- Jun 19, 2030patentUS 8545884*PED3.6y
- Apr 10, 2030patentUS 8426586*PED3.4y
- Apr 10, 2030patentUS 8426586*PED3.4y
- Apr 10, 2030patentUS 8426586*PED3.4y
- Dec 19, 2029formulationUS 85458843.1y
- Dec 19, 2029formulationUS 85458843.1y
- Dec 19, 2029formulationUS 85458843.1y
- Oct 10, 2029compositionUS 84265862.9y
- Oct 10, 2029compositionUS 84265862.9y
- Oct 10, 2029compositionUS 84265862.9y
- May 9, 2027patentUS 9539258*PED170d
- May 9, 2027patentUS 9539258*PED170d
- May 9, 2027patentUS 9539258*PED170d
- Nov 9, 2026method-of-use (U-1950)US 9539258
- Nov 9, 2026method-of-use (U-1950)US 9539258
- Nov 9, 2026method-of-use (U-1950)US 9539258
- Jul 13, 2026patentUS RE43431*PED
- Jul 13, 2026patentUS RE43431*PED
- Jul 13, 2026patentUS RE43431*PED
- Jan 13, 2026compositionUS RE43431
- Jan 13, 2026compositionUS RE43431
- Jan 13, 2026compositionUS RE43431
News(1)
- ArriVent sheds nearly half of value on late-stage lung cancer missArriVent BioPharma’s Phase 3 lung cancer trial was clouded by stronger-than-expected data for patients receiving chemotherapy, prompting analysts to pivot focus to a late-stage test of the tyrosine…biospace · 1mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that